CD31

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

Retrieved on: 
Monday, October 3, 2022
Inflammation, Heart Failure Society of America, Pharmacist, NASDAQ, Pulmonary fibrosis, Adult, History, News, Physician, Degenerative disease, Secondary research, Wound healing, Research, IND, Vimentin, Cannabidiol, Hospital, Fibrosis, Fatigue, FDA, Reversible process (thermodynamics), COVID-19, Education, Death, Risk, Pericardium, Practitioner, ARCHER, Therapy, Safety, Quality of life, Science, API, Cardiovascular disease, Patient, Heart failure, Biomarker, CRDL, CVD, Blood, CD31, Nursing, TSX, Company, Myocarditis, Pharmaceutical industry, Vaccine, HUVEC

Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022

Key Points: 
  • The authors concluded that the API in CardiolRx protects cardiac function and exhibits an anti-fibrotic effect, possibly mediated by endothelial-to-mesenchymal transition ("EndoMT").
  • "Our research collaborators from Houston Methodist DeBakey Heart & Vascular Center have previously shown that CardiolRx preserves cardiac function in a pre-clinical model of heart failure.
  • The results of the present study provide further evidence of the cardioprotective properties of CardiolRx that suggest anti-fibrotic mechanisms with therapeutic potential in heart failure," stated Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development.
  • These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information.

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Al

Retrieved on: 
Thursday, September 8, 2022
Neoplasm, Squamous cell carcinoma, COVID-19, Glioblastoma, Technology, GBM, Frontiers, XV, Research, Alpha Sigma Tau, Immunity, Immunophenotyping, MDSC, Brain, Trial of the century, Time, Xi, Gene expression, Canadian International Council, ASTRO, Risk, Mouse, Society, Biology, Blood, VEGF, DNA repair, DNA, SEC, U.S. Securities and Exchange Commission, SCC, Pembrolizumab, 100,000, PD-1, TMZ, GLOBE, CD31, Nasdaq, FDA, Immune system, American Society for Radiation Oncology, Cell death, Cell proliferation, RNA transfection, Annual report, Private Securities Litigation Reform Act, CTO, Vii, Alpha Tau Delta, Patient, Medical imaging, Pharmaceutical industry, Vaccine, Oncology, Bevacizumab, Physics, Radiation therapy, Tel Aviv University, Alpha

JERUSALEM, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (Nasdaq: DRTS and DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the acceptance of two landmark pre-clinical studies in major peer-reviewed journals, both demonstrating the significant potential synergies between Alpha DaRT therapy and standard-of-care solid tumor therapies used today.

Key Points: 
  • We are very excited to have these fantastic results recognized by two leading journals in our field, said Alpha Tau CEO Uzi Sofer.
  • We also are impressed by the synergies we see with other mechanisms such as anti-angiogenesis and continue to explore those in parallel as well.
  • These results demonstrate potential synergies with immune stimulation in mice and support the further exploration of the Alpha DaRT as a compelling local radiation therapy with the potential to induce antitumor immunity.
  • In this pre-clinical study, Squamous Cell Carcinoma (SCC) tumor-bearing mice were treated with Alpha DaRT in combination with an anti-PD1 therapy (aPD-1).